Pricing
  1. JP-listed companies
  3. Financials
  4. Return on Assets

(4586)

Market cap
¥6.6B
P/E ratio
Medrex develops new pharmaceuticals using proprietary skin-patch delivery technology that improves drug effectiveness and reduces side effects.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndReturn on Assets (Million JPY)YoY (%)
Dec 31, 2025-42.3+13.44%
Dec 31, 2024-37.3-31.05%
Dec 31, 2023-54.1-14.68%
Dec 31, 2022-63.4+31.72%
Dec 31, 2021-48.1-6.24%
Dec 31, 2020-51.3-30.81%
Dec 31, 2019-74.2+30.01%
Dec 31, 2018-57+68.06%
Dec 31, 2017-33.9-18.35%
Dec 31, 2016-41.6+57.64%
Dec 31, 2015-26.4

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat